Search Results - "Ray, Emily M."

Qualitative evaluation of barriers and facilitators to hepatocellular carcinoma care in North Carolina by Ray, Emily M, Teal, Randall W, Carda-Auten, Jessica, Coffman, Erin, Sanoff, Hanna K

“…Many patients with hepatocellular carcinoma (HCC) never receive cancer-directed therapy. In order to tailor interventions to increase access to appropriate…”
Get full text

Trends in breast, colon, pancreatic, and uterine cancers in women during the COVID‐19 pandemic in North Carolina by Nyante, Sarah J., Deal, Allison M., Heiling, Hillary M., Kim, Kyung Su, Kuzmiak, Cherie M., Calhoun, Benjamin C., Ray, Emily M.

“…Importance The COVID‐19 pandemic led to reductions in primary care and cancer screening visits, which may delay detection of some cancers. The impact on…”
Get full text

A phase II single‐arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effects by Nakamura, Zev M., Deal, Allison M., Park, Eliza M., Stanton, Kate E., Lopez, Yesy E., Quillen, Laura J., O’Hare Kelly, Erin, Heiling, Hillary M., Nyrop, Kirsten A., Ray, Emily M., Dees, E. Claire, Reeder‐Hayes, Katherine E., Jolly, Trevor A., Carey, Lisa A., Abdou, Yara, Olajide, Oludamilola A., Rauch, Julia K., Joseph, Ranjit, Copeland, Anureet, McNamara, Megan A., Ahles, Tim A., Muss, Hyman B.

“…Background Cognitive difficulties have been described after chemotherapy for breast cancer, but there is no standard of care to improve cognitive outcomes in…”
Get full text

Predicting the Future by Studying the Past for Patients With Cancer Diagnosed in the Emergency Department by Ray, Emily M, Elston Lafata, Jennifer, Reeder-Hayes, Katherine E, Thompson, Caroline A

Get full text

Risk Factors for Return to the Emergency Department and Readmission in Patients With Hospital-Diagnosed Advanced Lung Cancer by Ray, Emily M., Hinton, Sharon P., Reeder-Hayes, Katherine E.

“…Advanced lung cancer (ALC) is a symptomatic disease often diagnosed in the context of hospitalization. The index hospitalization may be a window of opportunity…”
Get full text

Prevalence of Pathologic N2/N3 Disease in Postmenopausal Women with Clinical N0 ER+/HER2− Breast Cancer by Amlicke, Maire J., Park, Jihye, Agala, Chris B., Casey, Dana L., Ray, Emily M., Downs-Canner, Stephanie M., Spanheimer, Philip M.

“…Background The RxPONDER trial demonstrated that the 21-gene recurrence score can be used to guide adjuvant systemic therapy decisions in postmenopausal women…”
Get full text

ASO Visual Abstract: Prevalence of Pathologic N2/N3 Disease in Postmenopausal Women with Clinical N0 ER+/HER2– Breast Cancer by Amlicke, Maire J., Park, Jihye, Agala, Chris B., Casey, Dana L., Ray, Emily M., Downs-Canner, Stephanie M., Spanheimer, Philip M.

Get full text

Pharmacist-facilitated Patient Reported Outcome Measure (PROM) monitoring: developing an EHR SmartForm© to monitor side effects of oral oncolytics during routine telehealth encounters by Stover, Angela M, Liang, Debbie, Mueller, Dana, Kurtzman, Rachel, Ikemeh, Christiana, Canter, Courtney, Acharya, Sonali, Brese, Jill, Buhlinger, Kaitlyn, Chen, Kevin, Colmenares, Evan W, Faso, Aimee, Muluneh, Benyam, Patel, Bianka, Reichard, Jeffrey S, Shah, Rushabh M, Tilkens, Michael, Valgus, John, Coombs, Lorinda A, Lafata, Jennifer Elston, Lund, Jennifer L, Ray, Emily M, Mody, Gita, Vest, Mary-Haston

“…Patient reported outcome measures (PROMs) are increasingly used in oncology care, but pharmacists providing direct patient care have been overlooked. We…”
Get full text

Quality of Life Outcomes in Breast Cancer Patients Receiving Chemotherapy With or Without Radiation Therapy by Morse, Ryan T., Bean, Nathan W., Hall, Jacob, Deal, Allison, Nyrop, Kirsten A., Abdou, Yara, Dees, Elizabeth C., Ray, Emily M., Jolly, Trevor A., Reeder-Hayes, Katherine E., Jones, Ellen, Gupta, Gaorav P., Elmore, Shekinah, Muss, Hyman B., Casey, Dana L.

“…Understanding quality of life (QOL) implications of individual components of breast cancer treatment is important as systemic therapies continue to improve…”
Get full text

Risk stratification and outreach to hematology/oncology patients during the COVID-19 pandemic by Osterman, Chelsea K., Triglianos, Tammy, Winzelberg, Gary S., Nichols, Angela D., Rodriguez-O’Donnell, Julia, Bigelow, Sharon M., van Deventer, Hendrik, Sanoff, Hanna K., Ray, Emily M.

“…Purpose Cancer patients have many medical and psychosocial needs, which may increase during the COVID-19 pandemic. We sought to (1) risk-stratify…”
Get full text

Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions by Ray, Emily M, Sanoff, Hanna K

“…The only US Food and Drug Administration (FDA)-approved first-line systemic therapy for hepatocellular carcinoma (HCC) is sorafenib; however, resistance or…”
Get full text

Assessing the Impact of a Novel Integrated Palliative Care and Medical Oncology Inpatient Service on Health Care Utilization before Hospice Enrollment by Ray, Emily M, Riedel, Richard F, LeBlanc, Thomas W, Rushing, Christel N, Galanos, Anthony N

“…Evidence increasingly supports the integration of specialist palliative care (PC) into routine cancer care. A novel, fully integrated PC and medical oncology…”
Get more information

Pleomorphic Invasive Lobular Carcinoma of the Breast With Extracellular Mucin and HER2 Amplification by Burky, Matthew J, Ray, Emily M, Ollila, David W, O’Connor, Siobhan M., Hertel, Johann D., Calhoun, Benjamin C

“…Invasive lobular carcinoma with extracellular mucin is an uncommon pattern of invasive breast carcinoma. The 5th Edition of the World Health Organization…”
Get full text

Breast Lesion Diameter in VisR Imaging Differs Between Malignant and Benign Masses in Women by Phillips, Anna V., Torres, Gabriela, Steed, Doreen, Caughey, Melissa C., Merhout, Jasmin, Kirk, Shanah R., Hartman, Terry S., Kuzmiak, Cherie M., Ray, Emily M., Gallippi, Caterina M.

“…The specificity of current clinical screening for identifying malignant breast lesions is as low as 65%, requiring costly and invasive additional tests to rule…”
Get full text

ARFI Variance of Acceleration for Diagnostic Breast Cancer Imaging in Women, in vivo by Phillips, Anna V., Torres, Gabriela, Steed, Doreen, Caughey, Melissa C., Merhout, Jasmin, Kirk, Shanah R., Hartman, Terry S., Kuzmiak, Cherie M., Ray, Emily M., Gallippi, Caterina M.

“…Early detection of breast cancer greatly aids survival. However, the specificity of current screening methods for identifying malignancy is poor, requiring…”
Get full text

Qualitative evaluation of barriers and facilitators to hepatocellular carcinoma care in North Carolina by Emily M. Ray, Randall W. Teal, Jessica Carda-Auten, Erin Coffman, Hanna K. Sanoff

“…Background Many patients with hepatocellular carcinoma (HCC) never receive cancer-directed therapy. In order to tailor interventions to increase access to…”
Get full text

Race and place: complex constructs in breast cancer care by Ray, Emily M., Wheeler, Stephanie B., Reeder-Hayes, Katherine E.

Get full text

Pleomorphic Invasive Lobular Carcinoma of the Breast With Extracellular Mucin and Amplification by Matthew J Burky, Emily M Ray, David W Ollila, Siobhan M. O’Connor, Johann D. Hertel, Benjamin C Calhoun

“…Invasive lobular carcinoma with extracellular mucin is an uncommon pattern of invasive breast carcinoma. The 5th Edition of the World Health Organization…”
Get full text